Table 3.
Impact of OCM on adherence to oral drugs for CML, prostate cancer, and hormonal therapy for breast cancer by race and ethnicity
| Proportion of days covered | No. of episodes |
OCM proportion of days covered |
Comparison proportion of days covered |
Impact estimates |
||||
|---|---|---|---|---|---|---|---|---|
| OCM | Comparison | Baseline, % | Intervention, % | Baseline, % | Intervention, % | DID (90% CI), % | P a | |
| Tyrosine kinase inhibitors for chronic myelogenous leukemia | ||||||||
| Black | 1056 | 1305 | 82.7 | 85.1 | 85.2 | 84.7 | 3.0 (0.2 to 5.8) | .08 |
| Hispanic | 881 | 822 | 84.9 | 84.2 | 86.9 | 88.9 | −2.7 (−6.5 to 1.1) | .25 |
| White | 9619 | 10 636 | 88.5 | 86.4 | 88.3 | 86.8 | −0.6 (−1.6 to 0.4) | .33 |
| Enzalutamide or abiraterone for prostate cancer | ||||||||
| Black | 2809 | 3517 | 86.0 | 84.4 | 87.2 | 83.3 | 2.2 (0.2 to 4.3) | .08 |
| Hispanic | 1315 | 1407 | 87.0 | 84.0 | 88.3 | 85.0 | 0.3 (−2.6 to 3.2) | .88 |
| White | 17 956 | 21 895 | 89.2 | 84.3 | 89.5 | 84.7 | 0.0 (−0.8 to 0.9) | .96 |
| Hormonal therapy for breast cancer | ||||||||
| Black | 18 778 | 20 313 | 88.6 | 89.2 | 88.3 | 89.2 | −0.3 (−1.0 to 0.3) | .38 |
| Hispanic | 11 377 | 10 551 | 89.4 | 90.0 | 89.8 | 89.9 | 0.6 (−0.2 to 1.4) | .24 |
| White | 199 087 | 211 787 | 90.6 | 91.0 | 90.9 | 91.3 | 0.1 (−0.1 to 0.3) | .54 |
Impact estimates and 2-sided P values based on difference-in-differences regression analysis. CI = confidence interval; CML = chronic myelogenous leukemia; DID = difference-in-difference estimate; OCM = Oncology Care Model intervention group.